NCT03334487 2018-12-26Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Small Cell Lung CancerAbbViePhase 3 Withdrawn
NCT00531284 2017-08-15Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or LymphomaAmgenPhase 1/2 Completed184 enrolled 36 charts